Tygacil

Complicated skin & skin structure infections (cSSSI) including those w/ MRSA, complicated intra-abdominal infections (cIAI), & community-acquired pneumonia (CAP) in adults. cSSSI including those w/ MRSA, & cIAI in childn ≥8 yr in situations where other alternative antibiotics are not suitable.

IV infusion Administer over approx 30-60 min every 12 hr. Adult Initially 100 mg, followed by 50 mg 12 every hr. Duration of treatment: 5-14 days (cSSSI or cIAI) or 7-14 days (CAP). Adult w/ severe hepatic impairment 100 mg followed by 25 mg every 12 hr. Childn 12-17 yr 50 mg every 12 hr, 8-11 yr 1.2 mg/kg every 12 hr to a max of 50 mg every 12 hr.

Hypersensitivity.

Not for diabetic foot infections & hospital-acquired or ventilator-associated pneumonia. Reports of anaphylactic reaction/anaphylactoid reactions; pseudomembranous colitis; isolated cases of significant hepatic dysfunction & failure. May be associated w/ permanent tooth discoloration during tooth development. Caution when considering monotherapy in patients w/ cIAI secondary to clinically apparent intestinal perforation. May have similar adverse effects to tetracyclines eg, photosensitivity, pseudotumor cerebri, pancreatitis, anti-anabolic action. Risk of acute pancreatitis; discontinue in case of suspected pancreatitis. Monitor blood coagulation parameters, including blood fibrinogen, prior to treatment initiation & regularly while on treatment. May result in overgrowth of non-susceptible organisms including fungi. Monitor LFTs, coagulation & hematology parameters, amylase & lipase prior to treatment initiation & regularly while on treatment, when used in childn. Patients w/ known hypersensitivity to tetracycline class antibiotics; patients w/ severe hepatic impairment. May affect ability to drive or operate machinery. Pregnancy & lactation. Do not use in childn <8 yr.

Nausea, vomiting, diarrhea. Prolonged aPTT & prothrombin time, thrombocytopenia; hypoproteinemia, hypoglycemia, decreased appetite; dizziness, headache; phlebitis; pneumonia; abdominal pain, dyspepsia; increased AST & ALT, hyperbilirubinemia; pruritus, rash; impaired healing, inj site reaction; increased amylase & BUN.

Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered w/ warfarin. Coadministration of P-gp inhibitors (eg, ketoconazole or cyclosporine) or P-gp inducers (eg, rifampicin) could affect tigecycline pharmacokinetics. Reduced effectiveness of OCs. Increased serum trough conc of calcineurin inhibitors eg, tacrolimus or cyclosporine.

Tetracyclines

J01AA12 - tigecycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.

Rx